Intrinsiqs

Is Mineralys Therapeutics, Inc. overvalued?

Mineralys Therapeutics, Inc. (MLYS) — key valuation metrics and fundamentals.

No verdict
Price
$25.52
Fair value
Current P/E
Normal P/E
Market cap
$2.25B
Dividend yield
0.0%
Return on equity
-27.9%
Sector
Healthcare

See the full interactive analysis →

Fair value compares MLYS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.